IQVIA Holdings stock kpis
Want to see IQV full AI Analyst Report?
Revenue by Segment
IQVIA Holdings reported revenue by segment of $4.43B in Q3 2026, up 1.4% from Q2 2026 and up 8.0% year over year. This is the highest value since 2020.
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments.
IQVIA’s growth engine is shifting toward Research and Development Solutions, which has accelerated steadily and aligns with record clinical bookings, stronger win rates, and rising trial activity. The apparent emergence of Commercial Solutions in 2026 likely reflects a reporting reclassification rather than entirely new revenue, making historical segment comparisons unreliable; nevertheless, management confirmed nearly 8% constant-currency growth and broad-based momentum in commercial offerings. Technology and Analytics also reached a new high before its apparent reallocation, while Contract Sales and Medical Solutions remain comparatively modest. AI adoption could further support commercial growth and future margins.
IQV Revenue by Segment
| Period | Technology and Analytics Solutions | Research and Development Solutions | Contract Sales and Medical Solutions | Commercial Solutions | Total |
|---|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $0.00 | $2.64B | $0.00 | $1.79B | $4.43B |
| Q2 2026Jun 30, 2026 | $0.00 | $2.58B | $0.00 | $1.79B | $4.37B |
| Q1 2026Mar 31, 2026 | $0.00 | $2.40B | $0.00 | $1.75B | $4.15B |
| Q4 2025Dec 31, 2025 | $1.82B | $2.33B | $210.00M | $0.00 | $4.36B |
| Q3 2025Sep 30, 2025 | $1.63B | $2.26B | $209.00M | $0.00 | $4.10B |
| Q2 2025Jun 30, 2025 | $1.63B | $2.20B | $188.00M | $0.00 | $4.02B |
| Q1 2025Mar 31, 2025 | $1.55B | $2.10B | $181.00M | $0.00 | $3.83B |
| Q4 2024Dec 31, 2024 | $1.66B | $2.12B | $177.00M | $0.00 | $3.96B |
| Q3 2024Sep 30, 2024 | $1.55B | $2.16B | $180.00M | $0.00 | $3.90B |
| Q2 2024Jun 30, 2024 | $1.50B | $2.15B | $172.00M | $0.00 | $3.81B |
| Q1 2024Mar 31, 2024 | $1.45B | $2.10B | $189.00M | $0.00 | $3.74B |
| Q4 2023Dec 31, 2023 | $1.53B | $2.15B | $186.00M | $0.00 | $3.87B |
| Q3 2023Sep 30, 2023 | $1.43B | $2.12B | $183.00M | $0.00 | $3.74B |
| Q2 2023Jun 30, 2023 | $1.46B | $2.10B | $176.00M | $0.00 | $3.73B |
| Q1 2023Mar 31, 2023 | $1.44B | $2.03B | $182.00M | $0.00 | $3.65B |
| Q4 2022Dec 31, 2022 | $1.50B | $2.06B | $182.00M | $0.00 | $3.74B |
| Q3 2022Sep 30, 2022 | $1.40B | $1.98B | $183.00M | $0.00 | $3.56B |
| Q2 2022Jun 30, 2022 | $1.41B | $1.95B | $183.00M | $0.00 | $3.54B |
| Q1 2022Mar 31, 2022 | $1.44B | $1.93B | $195.00M | $0.00 | $3.57B |
| Q4 2021Dec 31, 2021 | $1.50B | $1.94B | $196.00M | $0.00 | $3.64B |
| Q3 2021Sep 30, 2021 | $1.34B | $1.85B | $201.00M | $0.00 | $3.39B |
| Q2 2021Jun 30, 2021 | $1.35B | $1.89B | $194.00M | $0.00 | $3.44B |
| Q1 2021Mar 31, 2021 | $1.35B | $1.87B | $193.00M | $0.00 | $3.41B |
| Q4 2020Dec 31, 2020 | $1.43B | $1.68B | $189.00M | $0.00 | $3.30B |
| Q3 2020Sep 30, 2020 | $1.21B | $1.40B | $179.00M | $0.00 | $2.79B |
| Q2 2020Jun 30, 2020 | $1.11B | $1.24B | $177.00M | $0.00 | $2.52B |
| Q1 2020Mar 31, 2020 | $1.12B | $1.44B | $196.00M | $0.00 | $2.75B |

